Aptose Biosciences
Corporate Headquarters
251 Consumers Road
Suite 1105
Toronto
Ontario
M2J 4R3
Canada
Website: http://aptose.com/
178 articles about Aptose Biosciences
-
Aptose Reports Results for the Fourth Quarter and Full Year 2021
3/22/2022
Aptose Biosciences Inc., a clinical-stage precision oncology company developing highly differentiated oral kinase inhibitors to treat hematologic malignancies, announced financial results for the three months and year ended December 31, 2021 and provided a corporate update.
-
Aptose to Report Fourth Quarter and Full Year 2021 Financial Results and Hold Conference Call on Tuesday, March 22, 2022
3/8/2022
Aptose Biosciences Inc. will report financial results for the year and quarter ended December 31, 2021, on Tuesday, March 22, 2022 after the close of the market, and provide a corporate update.
-
Aptose to Present at Oppenheimer’s 32nd Annual Healthcare Conference
3/1/2022
Aptose Biosciences Inc. today announced that William G. Rice, Ph.D., Chairman, President and Chief Executive Officer, and the Aptose management team will present and host one-on-one meetings at Oppenheimer’s 32nd Annual Healthcare Conference.
-
Aptose to Participate in Two Biotech Events in January 2022
12/29/2021
Aptose Biosciences Inc. today announced that the company will participate in two separate biotech events in January 2022: the H.C. Wainwright BIOCONNECT Virtual Conference and the 11th Annual LifeSci Partners Corporate Access Event.
-
Clinical Catch-Up: December 11-17
12/20/2021
It was an enormously busy week with plenty of announcements from the American Society of Hematology meeting and numerous companies working to get the news out ahead of the holidays and year-end. Here’s a look. -
Aptose Provides Update on APTO-253 Program
12/20/2021
Aptose Biosciences Inc. (“Aptose”) (NASDAQ: APTO, TSX: APS) today announced its decision to discontinue further clinical development of APTO-253.
-
HM43239 Demonstrates Durable Clinical Benefit in Acute Myeloid Leukemia
12/13/2021
Aptose Biosciences Inc. (“Aptose”) (NASDAQ: APTO, TSX: APS) today reported that the oral myeloid kinome inhibitor HM43239 has demonstrated durable single agent activity in patients with relapsed or refractory acute myeloid leukemia (AML).
-
Aptose to Hold Corporate Update Monday, December 13th
11/29/2021
Aptose Biosciences Inc. today announced that the company management team will provide a corporate update on Monday, December 13, 2021 at 5:30 PM ET.
-
Aptose to Present at the Piper Sandler 33rd Annual Healthcare Conference
11/22/2021
Aptose Biosciences Inc. (Nasdaq: APTO; TSX: APS), a clinical-stage company developing highly differentiated therapeutics that target the underlying mechanisms of cancer, today announced that the Aptose management team will be participating in the Piper Sandler 33rd Annual Healthcare Conference, being held virtually.
-
Aptose Reports Results for the Third Quarter 2021
11/11/2021
Aptose Biosciences Inc., a clinical-stage company developing highly differentiated agents that target the underlying mechanisms of cancer, announced financial results for the three months ended September 30, 2021 and provided a corporate update.
-
Aptose Enters into Exclusive Worldwide License Agreement with Hanmi Pharmaceutical for Clinical-Stage Myeloid Kinome Inhibitor HM43239
11/4/2021
Aptose Biosciences Inc., announced that it has entered into an exclusive license agreement with Hanmi Pharmaceutical, a South Korean pharmaceutical company, to develop and commercialize HM43239, an oral, highly potent, clinical-stage myeloid kinome inhibitor, designed to target a distinct constellation of kinases operative in myeloid malignancies, including SYK, FLT3, and others.
-
Aptose Clinical Data to be Presented at the 2021 ASH Annual Meeting
11/4/2021
Aptose Biosciences Inc. announced that clinical data for HM43239, a myeloid kinome inhibitor in-licensed by Aptose is being presented in an oral presentation at the 63rd American Society of Hematology Annual Meeting and Exposition, being held Saturday, December 11 – Monday, December 14, 2021 in Atlanta, GA and virtually.
-
Aptose to Report Third Quarter 2021 Financial Results and Hold Conference Call on Thursday, November 11, 2021
10/26/2021
Aptose Biosciences Inc. will report financial results for the quarter ended September 30, 2021, and provide a corporate update on Thursday, November 11, 2021, after the close of the market.
-
Aptose to Present at September 2021 Investor Conferences
8/30/2021
Aptose Biosciences Inc., a clinical-stage company developing highly differentiated therapeutics that target the underlying mechanisms of cancer, announced that the Aptose management team will participate at the upcoming conferences in September 2021
-
Aptose Reports Results for the Second Quarter 2021
8/3/2021
Aptose Biosciences Inc., a clinical-stage company developing highly differentiated agents that target the underlying mechanisms of cancer, announced financial results for the three months ended June 30, 2021 and provided a corporate update.
-
Aptose to Report Second Quarter 2021 Financial Results and Hold Conference Call on Tuesday, August 3, 2021
7/20/2021
Aptose Biosciences Inc. (Nasdaq: APTO; TSX: APS), a clinical stage company developing highly differentiated therapeutics that target the underlying mechanisms of cancer, will report financial results for the quarter ended June 30, 2021, and provide a corporate update on Tuesday, August 3, 2021, after the close of the market.
-
Aptose Presents Highlights from EHA During Corporate Update Event
6/11/2021
Aptose Biosciences Inc. is releasing highlights from a corporate update event being held today, Friday, June 11, 2021, at 8:00 a.m. ET.
-
Aptose Biosciences Announces Results of Annual Meeting of Shareholders - June 01, 2021
6/1/2021
Aptose Biosciences Inc., a clinical-stage company developing highly differentiated therapeutics that target the underlying mechanisms of cancer, announced the voting results from the Company’s annual and special meeting of shareholders held today, June 1, 2021.
-
Aptose to Hold Corporate Update Friday, June 11th
5/27/2021
Clinical Updates for Luxeptinib in AML & B-cell Cancers and for APTO-253 in AML & MDS Poster Presentations for CG-806 and APTO-253 are Scheduled for June 11th at EHA2021 Virtual Congress
-
Aptose to Present at Upcoming Investor Conferences
5/12/2021
- Aptose Biosciences Inc. (Nasdaq: APTO; TSX: APS), a clinical-stage company developing highly differentiated therapeutics that target the underlying mechanisms of cancer, today announced that the Aptose management team will participate in upcoming investor conferences: 2021 RBC Capital Markets Global Healthcare Virtual Conference Date: Wednesday, May 19, 2021 Time: 11:30 AM – 11:55 AM EDT